# Study of Sacituzumab Govitecan in Patients With Solid Tumor

Source: https://onco.cc/trials/nct05119907/  
OnCo record `nct05119907` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan in Patients With Solid Tumor is a phase 2 interventional study registered as NCT05119907 by Gilead Sciences, with 53 participants enrolled, started 2021-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: Sacituzumab Govitecan-hziy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05119907
- Phase: 2
- Setting: A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor
- Sponsor: Gilead Sciences
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT05119907: https://clinicaltrials.gov/study/NCT05119907

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05119907.json